Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Oritavancin in Infective Endocarditis
3.2. Oritavancin in Catheter- or Device-Related Infections
3.3. Oritavancin in Isolated Blood-Stream Infections
3.4. Oritavancin in Bone and Prosthetic Joint Infections
3.5. Oritavancin and Biofilm
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tran, T.T.; Gomez Villegas, S.; Aitken, S.L.; Butler-Wu, S.M.; Soriano, A.; Werth, B.J.; Munita, J.M. New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides. Antimicrob. Agents Chemother. 2022, 66, e0261420. [Google Scholar] [CrossRef] [PubMed]
- Karaoui, L.R.; El-Lababidi, R.; Chahine, E.B. Oritavancin: An investigational lipoglycopeptide antibiotic. Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm. 2013, 70, 23–33. [Google Scholar] [CrossRef] [PubMed]
- Sintesi di Tenkasi e Perché è Autorizzato Nell’unione Europea (UE). Available online: https://www.ema.europa.eu/en/documents/overview/tenkasi-previously-orbactiv-epar-summary-public_it.pdf (accessed on 5 November 2022).
- Highlights of Prescribing Information. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206334s005lbl.pdf (accessed on 5 November 2022).
- Hoover, R.K.; Krsak, M.; Molina, K.C.; Shah, K.; Redell, M. Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties. Open Forum Infect. Dis. 2022, 9, ofac090. [Google Scholar] [CrossRef] [PubMed]
- Saddler, K.; Zhang, J.; Sul, J.; Patel, P.; Castro-Lainez, M.; Stevens, M.L.; Kosler, S.; Lowery, E.; Sierra-Hoffman, M. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital. PLoS ONE 2021, 16, e0248129. [Google Scholar] [CrossRef]
- Belley, A.; Robson, R.; Francis, J.L.; Adcock, D.M.; Tiefenbacher, S.; Rubino, C.M.; Moeck, G.; Sylvester, D.; Dudley, M.N.; Loutit, J. Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory. Antimicrob. Agents Chemother. 2017, 61, e01968-16. [Google Scholar] [CrossRef] [Green Version]
- Corey, G.R.; Kabler, H.; Mehra, P.; Gupta, S.; Overcash, J.S.; Porwal, A.; Giordano, P.; Lucasti, C.; Perez, A.; Good, S.; et al. SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N. Engl. J. Med. 2014, 370, 2180–2190. [Google Scholar] [CrossRef] [Green Version]
- Corey, G.R.; Good, S.; Jiang, H.; Moeck, G.; Wikler, M.; Green, S.; Manos, P.; Keech, R.; Singh, R.; Heller, B.; et al. SOLO II Investigators. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II non-inferiority study. Clin. Infect. Dis. 2015, 60, 254–262. [Google Scholar] [CrossRef] [Green Version]
- Bassetti, M.; Labate, L.; Vena, A.; Giacobbe, D.R. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. Curr. Opin. Infect. Dis. 2021, 34, 96–108. [Google Scholar] [CrossRef]
- Baethge, C.; Goldbeck-Wood, S.; Mertens, S. SANRA-a scale for the quality assessment of narrative review articles. Res. Integr. Peer Rev. 2019, 4, 5. [Google Scholar] [CrossRef] [Green Version]
- Johnson, J.A.; Feeney, E.R.; Kubiak, D.W.; Corey, G.R. Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis. Open Forum Infect. Dis. 2015, 2, ofv156. [Google Scholar] [CrossRef] [Green Version]
- Stewart, C.L.; Turner, M.S.; Frens, J.J.; Snider, C.B.; Smith, J.R. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections. Infect. Dis. Ther. 2017, 6, 277–289. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brownell, L.E.; Adamsick, M.L.; McCreary, E.K.; Vanderloo, J.P.; Ernst, E.J.; Jackson, E.R.; Schulz, L.T. Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience. Drugs-Real World Outcomes 2020, 7 (Suppl. S1), 13–19. [Google Scholar] [CrossRef] [PubMed]
- Terrero Salcedo, D.A.; El-Herte, R.; Granada, M. Oritavancin for the Treatment of Infective Endocarditis due to Gram-positive Organism. Ann. Case Rep. 2018, ACRT-202. [Google Scholar] [CrossRef]
- Morrisette, T.; Miller, M.A.; Montague, B.T.; Barber, G.R.; McQueen, R.B.; Krsak, M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J. Antimicrob. Chemother. 2019, 74, 2405–2416. [Google Scholar] [CrossRef] [PubMed]
- Ahiskali, A.; Rhodes, H. Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs. BMC Pharmacol. Toxicol. 2020, 21, 73. [Google Scholar] [CrossRef]
- Schulz, L.T.; Dworkin, E.; Dela-Pena, J.; Rose, W.E. Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections. Pharmacotherapy 2018, 38, 152–159. [Google Scholar] [CrossRef]
- Co, D.; Roebuck, L.; VanLandingham, J. Evaluation of Oritavancin Use at a Community Hospital. Hosp. Pharm. 2018, 53, 272–276. [Google Scholar] [CrossRef]
- Redell, M.; Sierra-Hoffman, M.; Assi, M.; Bochan, M.; Chansolme, D.; Gandhi, A.; Sheridan, K.; Soosaipillai, I.; Walsh, T.; Massey, J. The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections. Open Forum Infect. Dis. 2019, 6, ofz479. [Google Scholar] [CrossRef]
- Van Hise, N.W.; Chundi, V.; Didwania, V.; Anderson, M.; McKinsey, D.; Roig, I.; Sharma, A.; Petrak, R.M. Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study. Drugs Real World Outcomes 2020, 7, 41–45. [Google Scholar] [CrossRef]
- Delaportas, D.J.; Estrada, S.J.; Darmelio, M. Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy 2017, 37, e90–e92. [Google Scholar] [CrossRef]
- Chastain, D.B.; Davis, A. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review. Int. J. Antimicrob. Agents 2019, 53, 429–434. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, J.P.; Contreras, B.X.; Sierra-Hoffman, M.; Saddler, K.; Stevens, M.L.; Castro-Lainez, M.T.; Knox, B.; Deliz, R.J. Successful treatment of a prosthetic hip infection due to Enterococcus faecalis with sequential dosing of oritavancin and prosthesis preservation without prosthetic joint surgical manipulation. IDCases 2020, 22, e00949. [Google Scholar] [CrossRef] [PubMed]
- Dahesh, S.; Wong, B.; Nizet, V.; Sakoulas, G.; Tran, T.T.; Aitken, S.L. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin. Antimicrob. Agents Chemother. 2019, 63, e02622-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oritavancin for Staphylococcus Aureus Infections in Opioid Users. Available online: https://clinicaltrials.gov/ct2/show/NCT03761953 (accessed on 5 November 2022).
- Meyer, J.; Lata, P.; Barnett, S. Continued Dosing of Oritavancin for Complicated Gram-Positive Infections. Fed. Pract. 2020, 37, 502–504. [Google Scholar] [CrossRef]
- Rose, W.E.; Hutson, P.R. A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis. Drugs-Real World Outcomes 2020, 7 (Suppl. S1), 36–40. [Google Scholar] [CrossRef]
- Carvalhaes, C.G.; Sader, H.S.; Streit, J.M.; Mendes, R.E. Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017–2019). Open Forum Infect. Dis. 2022, 9, ofac492.698. [Google Scholar] [CrossRef]
- Bhavnani, S.M.; Passarell, J.A.; Owen, J.S.; Loutit, J.S.; Porter, S.B.; Ambrose, P.G. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2006, 50, 994–1000. [Google Scholar] [CrossRef] [Green Version]
- Belley, A.; Neesham-Grenon, E.; McKay, G.; Arhin, F.F.; Harris, R.; Beveridge, T.; Parr, T.R., Jr.; Moeck, C. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob. Agents Chemother. 2009, 53, 918–925. [Google Scholar] [CrossRef] [Green Version]
- Yan, Q.; Karau, M.J.; Patel, R. In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection. Diagn. Microbiol. Infect. Dis. 2018, 92, 155–157. [Google Scholar] [CrossRef]
- Lin, G.; Pankuch, G.; Appelbaum, P.C.; Kosowska-Shick, K. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents. Antimicrob. Agents Chemother. 2014, 586, 251–6254. [Google Scholar] [CrossRef] [Green Version]
- Smith, J.R.; Yim, J.; Raut, A.; Rybak, M.J. Oritavancin combinations with beta-lactams against multidrug-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 2016, 60, 2352–2358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, Q.; Karau, M.J.; Raval, Y.S.; Patel, R. Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays. Antimicrob. Agents Chemother. 2018, 62, e00943-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, Q.; Karau, M.J.; Patel, R. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci. Diagn. Microbiol. Infect. Dis. 2018, 91, 348–350. [Google Scholar] [CrossRef] [PubMed]
- Lagatolla, C.; Mehat, J.W.; La Ragione, R.M.; Luzzati, R.; Di Bella, S. In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium. Antibiotics 2022, 11, 1334. [Google Scholar] [CrossRef]
- Antony, S.J.; Cooper, L.G. Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem. Infect. Disord. Drug Targets 2017, 17, 77–80. [Google Scholar] [CrossRef]
- Pfaller, M.A.; Sader, H.S.; Shortridge, D.; Flamm, R.K.; Mendes, R.E. Analysis of Oritavancin Activity Against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016). Open Forum Infect. Dis. 2017, 4, 369. [Google Scholar] [CrossRef]
Infective Endocarditis | ||||||
First Author et al. (Year) [Ref] | Type of Study | N. of Patients Treated, Type of Infection | Dosing and Interval | Pathogen (s) | Outcome | Adverse Effects |
Johnson et al. (2015) [12] | Case Report | 1 (1), PVE | 1200 q48h × 3; 1200 twice weekly for 6 wks; After recurrence 2 wks twice weekly in combination with gentamicin (4 days) and then linezolid and tigecicline; 10 wks after surgery 1200 twice weekly (in the first ten days in addition with linezolid and tigecycline) | VRE | Favourable after surgical valve replacement | Increased aPTT; nausea and anorexia (during combination therapy with linezolid and tigecycline) |
Stewart et al. (2017) [13] | Case Series | 1 (10), NVE | 1200 single dose (after 3 days of vancomycin and 4 days of ceftriaxone) | Group B Streptococcus | Failure due to the need for surgical intervention and hospital readmission 3 months later | None |
Salcedo et al. (2018) [15] | Case Series | 5 (5), NVE | 1200 single dose in 3 patiens, 1200 weekly × 4 in 2 patients | 2 MSSA, 2 MRSA and 1 GBS/GFS | 3 favourable. 2 Not reported | One patients reported eosinophilia/anaphylaxis |
Brownell et al. (2020) [14] | Retrospective, observational | 4 (75), Endocarditis not specified | NA | NA | Favourable in 100% of cases | NA |
Morrisette et al. (2019) [16] | Retrospective, multicenter | 1 (56), Endocarditis | 1200 single dose, then lost to follow-up | E. faecalis | Lost to follow-up | NA |
Ahiskali et al. (2020) [17] | Retrospective, observational | 2 (24), Endocarditis not specified | 1200 single dose in 1 patients, 1200 weekly × 2 in 1 patient | 1 MSSA and 1 MRSA | Clinical cure (MSSA). Failure (complicated by spondylodiscitis and epidural abscess) | NA |
Device-Related Infections | ||||||
First Author et al. (Year) [Ref] | Type of Study | N. of Patients Treated | Dosing and Interval | Pathogen(s) | Outcome | Adverse Effects |
Stewart et al. (2017) [13] | Case Series | 1 (10), CLABSI | 1200 single dose (after 4 days of vancomycin and 1 days of cefazoline) | MSSA | Favourable | Nausea |
Shulz et al. (2018) [18] | retrospective, observational | 1 (17), endovascular graft infection | 1200 mg × 1; 800 mg/wk × 11 doses; 1200 mg × 1 following 11-day intervals; and 800 mg × 5/wk | S. lugdunensis | Palliative intent | NA |
Morrisette et al. (2019) [16] | Retrospective, multicenter | 2 (56), CLABSI | NA | NA | NA | NA |
Co et al. (2018) [19] | Retrospective, observational | 7 (67), cardiac device infection | NA | NA | NA | NA |
Brownell et al. (2020) [14] | Retrospective, observational | 2 (75), Line infection | NA | NA | Favourable in 100% of cases | NA |
Redell et al. (2019) [20] | Retrospective, observational | 2 (440), 1 exit site infection, 1 Spinal Hardware | 1200 single dose | NA | NA | NA |
Blood-Stream Infections | ||||||
First Author et al. [Ref] | Type of Study | N. of Patients Treated | Dosing and Interval | Pathogen(s) | Outcome | Adverse Effects |
Stewart et al. (2017) [13] | Case Series | 6 (10), isolated BSI | 1200 single dose | 4 MSSA, 1 enterococcus (Ampicillin-susceptible) and 1 CoNS | 4 Favourable, 1 Failure and 1 Not evaluable | None |
Ahiskali et al. (2020) [17] | Retrospective, observational | 3 (24), isolated BSI | 1200 single dose in 5 patients, 1200 weekly × 2 in 2 patient, 1200 weekly × 4 in 1 patient | 5 MRSA and 4 MSSA | 3 complete cure, 4 incomplete cure, 2 lost at FUP | NA |
Redell et al. (2019) [20] | Retrospective, observational | 7 (440), isolated BSI | 1200 single dose | NA | NA | NA |
Prosthetic Joint Infections | ||||||
First Author et al. [Ref] | Type of Study | N. of Patients Treated | Dosing and Interval | Pathogen(s) | Outcome | Adverse Effects |
Van Hise et al. (2020) [21] | multicenter, retrospective, descriptive | 134 ostheomyelitis, of which 24 prosthetic | 1200 mg, then 800 mg weekly (4 to 5 doses) | 71.9% MRSA | 88.1% clinical success at the end of therapy | 3 hypoglycemia, 1 tachycardia, 1 tachycardia with chest pain |
Redell et al. (2019) [20] | retrospective, observational | 438, of which 18 osteomyelitis and 3 prosthetic | 1200 mg every 6–14 days (1–10 doses) | 74% S. aureus of which 59.3% MRSA | 93.8% cure or 30-days improvement | 6.6% of patients reported an adverse event |
Shulz et al. (2018) [18] | retrospective, observational | 17 including osteomyelitis | 1200 mg (2–18 doses) | NA | 100% clinical success or improvement | 24% of patients reported an adverse event |
Delaportas et al. (2017) [22] | case report | 1 ostheomyelitis | 1200 mg weekly (6 doses) | MSSA | clinical cure | NA |
Chastain et al. (2018) [23] | case series | 9 chronic ostheomyelitis | 1200 mg—variable time between doses (2–6 doses) | 5 MRSA | 100% clinical cure at 6-months follow up | None |
Nguyen et al. (2020) [24] | case report | 1 prosthetic joint infection | daptomycin plus ampicillin 10 days, then 1200 mg weekly (6 doses) | vancomycin sensitive E. faecalis | clinical cure | NA |
Dahesh et al. (2019) [25] | case report | 1 prosthetic vertebral ostheomyelitis | 1200 mg weekly (2 doses), then 800 mg weekly (8 doses) plus ampicillin | vancomycin-resistant E. faecium | clinical cure | NA |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lupia, T.; De Benedetto, I.; Bosio, R.; Shbaklo, N.; De Rosa, F.G.; Corcione, S. Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments. Life 2023, 13, 959. https://doi.org/10.3390/life13040959
Lupia T, De Benedetto I, Bosio R, Shbaklo N, De Rosa FG, Corcione S. Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments. Life. 2023; 13(4):959. https://doi.org/10.3390/life13040959
Chicago/Turabian StyleLupia, Tommaso, Ilaria De Benedetto, Roberta Bosio, Nour Shbaklo, Francesco Giuseppe De Rosa, and Silvia Corcione. 2023. "Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments" Life 13, no. 4: 959. https://doi.org/10.3390/life13040959